(3S)-3,4-dihydroxybutyronitrile

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (3S)-3,4-dihydroxybutyronitrile
• 英文别名: (3S)-3,4-dihydroxybutanenitrile；S-3,4-dihydroxybutyronitrile；(S)-3,4-dihydroxy butyronitrile；(S)-3,4-Dihydroxybutanenitrile
• 化学式: C₄H₇NO₂
• 分子量: 101.105
• InChiKey: MXKPBRJADBPHSC-BYPYZUCNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  7
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  64.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (3S)-3,4-dihydroxybutyronitrile 在 吡啶 作用下， 以 盐酸 为溶剂， 以57%的产率得到(S)-3-hydroxy-4-(methanesulfonyloxy)butyronitrile
  参考文献：
  名称：

  Process for the production of 3,4-epoxybutyrate and intermediate therefor

  摘要：

  一种公式为##STR1##的3,4-环氧丁酸酯，其中R1是烷基或芳基烷基，可通过以下步骤高效制备：(a)在碱的存在下，将公式为##STR2##的3,4-二羟基丁腈与公式为R2-SO2-Cl的磺酰氯反应，其中R2是烷基或可能被取代的苯基，以获得公式为##STR3##的化合物；(b)在酸的存在下，将步骤(a)中制备的化合物与公式为R1-OH的醇反应，以获得公式为##STR4##的化合物；(c)将步骤(b)中制备的化合物与碱反应，以获得3,4-环氧丁酸酯。

  公开号：

  US05079382A1
• 作为产物：
  描述：

  (S)-2,2-二甲基-1,3-二氧戊环-4-乙腈 在 三氟乙酸 作用下， 以 甲醇 为溶剂， 反应 1.5h， 以61%的产率得到(3S)-3,4-dihydroxybutyronitrile
  参考文献：
  名称：

  A Novel Agonist of the Type 1 Lysophosphatidic Acid Receptor (LPA₁), UCM-05194, Shows Efficacy in Neuropathic Pain Amelioration

  摘要：

  Neuropathic pain (NP) is a complex chronic pain state with a prevalence of almost 10% in the general population. Pharmacological options for NP are limited and weakly effective, so there is a need to develop more efficacious NP attenuating drugs. Activation of the type 1 lysophosphatidic acid (LPA(1)) receptor is a crucial factor in the initiation of NP. Hence, it is conceivable that a functional antagonism strategy could lead to NP mitigation. Here we describe a new series of LPA(1) agonists among which derivative (S)-17 (UCM-05194) stands out as the most potent and selective LPA(1) receptor agonist described so far (E-max = 118%, EC50 = 0.24 mu M, KD = 19.6 nM; inactive at autotaxin and LPA(2-6) receptors). This compound induces characteristic LPA(1)-mediated cellular effects and prompts the internalization of the receptor leading to its functional inactivation in primary sensory neurons and to an efficacious attenuation of the pain perception in an in vivo model of NP.

  DOI：

  10.1021/acs.jmedchem.9b01287

文献信息

• Process for the production of 3,5,6-trihydroxyhexanoic acid derivative
  申请人：Kanegafuchi Chemical Industry Co., Ltd.

  公开号：US04983759A1

  公开（公告）日：1991-01-08

  A compound of a 3,5,6-trihydroxyhexanoic acid derivative of the formula: ##STR1## wherein P.sup.1 and P.sup.2 are independently hydrogen atoms or hydroxy-protecting groups, or together form a ring, and R is an alkyl group is effectively prepared by a process comprising steps of: reacting a butyronitrile derivative of the formula: ##STR2## wherein P.sup.1 and P.sup.2 are the same as defined above with an .alpha.-haloacetate of the formula: X--CH.sub.2 --COOR (III) wherein X is a halogen atom, and R is the same as defined above in the presence of a metallic catalyst selected from the group consisting zinc and zinc-copper to form a keto acid derivative of the formula: ##STR3## wherein P.sup.1, P.sup.2 and R are the same as defined above, and then reducing the obtained keto-acid derivative of the formula (IV).

  一种化合物，其为3,5,6-三羟基己酸衍生物，化学式如下：##STR1## 其中P1和P2分别是氢原子或羟基保护基，或者一起形成一个环，R为烷基基团，通过以下步骤有效制备：将以下化学式的丁腈衍生物：##STR2## 其中P1和P2的定义与上述相同，与以下化学式的α-卤代乙酸酯：X--CH2--COOR (III) 反应，其中X为卤素原子，R的定义与上述相同，在选择自锌和锌-铜组成的金属催化剂存在下，形成以下酮酸衍生物：##STR3## 其中P1、P2和R的定义与上述相同，然后还原得到的酮酸衍生物（IV）。
• A Novel Agonist of the Type 1 Lysophosphatidic Acid Receptor (LPA₁), UCM-05194, Shows Efficacy in Neuropathic Pain Amelioration
  作者：Inés González-Gil、Debora Zian、Henar Vázquez-Villa、Gloria Hernández-Torres、R. Fernando Martínez、Nora Khiar-Fernández、Richard Rivera、Yasuyuki Kihara、Isabel Devesa、Sakthikumar Mathivanan、Cristina Rosell del Valle、Emma Zambrana-Infantes、María Puigdomenech、Giovanni Cincilla、Melchor Sanchez-Martinez、Fernando Rodríguez de Fonseca、Antonio V. Ferrer-Montiel、Jerold Chun、Rubén López-Vales、María L. López-Rodríguez、Silvia Ortega-Gutiérrez

  DOI：10.1021/acs.jmedchem.9b01287

  日期：2020.3.12

  Neuropathic pain (NP) is a complex chronic pain state with a prevalence of almost 10% in the general population. Pharmacological options for NP are limited and weakly effective, so there is a need to develop more efficacious NP attenuating drugs. Activation of the type 1 lysophosphatidic acid (LPA(1)) receptor is a crucial factor in the initiation of NP. Hence, it is conceivable that a functional antagonism strategy could lead to NP mitigation. Here we describe a new series of LPA(1) agonists among which derivative (S)-17 (UCM-05194) stands out as the most potent and selective LPA(1) receptor agonist described so far (E-max = 118%, EC50 = 0.24 mu M, KD = 19.6 nM; inactive at autotaxin and LPA(2-6) receptors). This compound induces characteristic LPA(1)-mediated cellular effects and prompts the internalization of the receptor leading to its functional inactivation in primary sensory neurons and to an efficacious attenuation of the pain perception in an in vivo model of NP.
• Process for the production of 3,4-epoxybutyrate and intermediate therefor
  申请人：Kanegafuchi Chemical Industry Co., Ltd.

  公开号：US05079382A1

  公开（公告）日：1992-01-07

  A 3,4-epoxybutyrate of the formula: ##STR1## wherein R.sup.1 is an alkyl or aralkyl group is efficiently prepared by a process comprising steps of: (a) reacting 3,4-dihydroxybutyronitrile of the formula: ##STR2## with a sulfonyl chloride of the formula: R.sup.2 --SO.sub.2 --Cl wherein R.sup.2 is an alkyl group or a phenyl group which may be substituted in the presence of a base to obtain a compound of the formula: ##STR3## (b) reacting the compound prepared in the step (a) with an alcohol of the formula: R.sup.1 --OH in the presence of an acid to obtain a compound of the formula: ##STR4## and (c) reacting the compound prepared in the step (b) with a base to obtain the 3,4-epoxybutyrate.

  一种公式为##STR1##的3,4-环氧丁酸酯，其中R1是烷基或芳基烷基，可通过以下步骤高效制备：(a)在碱的存在下，将公式为##STR2##的3,4-二羟基丁腈与公式为R2-SO2-Cl的磺酰氯反应，其中R2是烷基或可能被取代的苯基，以获得公式为##STR3##的化合物；(b)在酸的存在下，将步骤(a)中制备的化合物与公式为R1-OH的醇反应，以获得公式为##STR4##的化合物；(c)将步骤(b)中制备的化合物与碱反应，以获得3,4-环氧丁酸酯。